Results 161 to 170 of about 12,551,552 (363)

Lung function trajectories in health and disease.

open access: yesThe Lancet Respiratory Medicine, 2019
A. Agustí, R. Faner
semanticscholar   +1 more source

Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case‐control study

open access: yesMolecular Oncology, EarlyView.
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima   +6 more
wiley   +1 more source

Functional Morphology of the Distal Lung

open access: yes, 1974
Publisher Summary This chapter reviews the information concerning the form and function of the distal lung, defined as terminal bronchioles, respiratory bronchioles, and alveolar ducts, from the viewpoint of cell biology. The chapter summarizes the data produced by microscopy, electron microscopy, biochemistry, and cell and tissue culture.
openaire   +3 more sources

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

open access: yesMolecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi   +12 more
wiley   +1 more source

Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis

open access: yesNature Genetics, 2017
B. Hobbs   +75 more
semanticscholar   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy